---
title: "Inside the Silent Rally of Hong Kong's Niche MedTech and Hardware Plays"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295514705.md"
description: "Small and mid-cap healthcare and tech stocks in Hong Kong are experiencing localized breakouts. With TrueHealth's massive IPO pop and solid clinical updates from InnoCare, niche plays are drawing fresh institutional interest."
datetime: "2026-08-11T09:43:58.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295514705.md)
  - [en](https://longbridge.com/en/news/295514705.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295514705.md)
generator: "portal-rs"
---

# Inside the Silent Rally of Hong Kong's Niche MedTech and Hardware Plays

Hong Kong's micro and small-cap sectors are experiencing a quiet but notable restructuring. I'm told that while the broader market remains sideways, institutional money is aggressively flowing into specialized MedTech plays and niche hardware suppliers capitalizing on AI narratives. Recent channel checks indicate that investors are heavily scrutinizing newly listed surgical robot makers and biotech firms making rapid clinical headway.

### TrueHealth (2697.HK)

Guangdong TrueHealth Medical Technology (2697.HK) sparked a frenzy when it debuted on the main board in late June 2026 as the first pure-play percutaneous surgical robot stock. According to people familiar with the matter, its shares skyrocketed over 200% on the first day of trading, reflecting intense institutional demand for scarce AI healthcare assets. The company holds a massive 36.4% market share in percutaneous robots by shipment in 2025, providing solid fundamental backing for its premium valuation in a volatile market.

### InnoCare (9887.HK)

Clinical-stage biotech InnoCare Pharma (9887.HK) has been aggressively advancing its Immuno-Oncology 2.0 therapies. I'm told that its core bispecific antibody, LBL-024, secured back-to-back clinical breakthroughs in early August 2026. The Phase II study for treating hepatocellular carcinoma has successfully entered the expansion stage, while its IND application for metastatic colorectal cancer was approved by the CDE. Industry insiders expect this pipeline progress to open the door for lucrative out-licensing deals later this year.

### The United Laboratories (3933.HK)

The United Laboratories International (3933.HK) has also trended upward over the past month. I've learned that in July 2026, the pharmaceutical veteran not only received an exclusive licensing milestone payment from Novo Nordisk for UBT251, but also secured rapid product approvals for new specifications like its sodium hyaluronate eye drops. This "cash cow plus new licensing" model is fundamentally reshaping how analysts value the company, drawing in funds seeking downside protection.

### 160 Health (2656.HK)

Digital healthcare platform 160 Health International (2656.HK) has shown relentless strength, hitting fresh highs this year. A recent profit alert indicated the company swung to an adjusted net profit of roughly RMB 3M to RMB 5M for the 2025 fiscal year. With the lock-up period for certain ordinary shares expiring in March 2026, the expanded free float is reportedly triggering a fresh wave of institutional re-evaluations.

### Man Yue Tech (0894.HK)

Man Yue Technology (0894.HK) was traditionally viewed as a legacy electronic component manufacturer, but it recently caught the AI boom tailwind, with its stock surging nearly 20% in a single session in early July. I'm told that its rollout of energy storage lithium carbon capacitors in late July 2026 is an aggressive move to break into the high-margin AI computing supply chain. Given its stable annual profits, speculative capital flow into the name remains highly active.

### Also

-   **Taung Gold (8299.HK)**: The gold miner issued a massive profit alert, projecting FY2026 revenue to jump 53% to HKD 2.005B and net profit to soar to HKD 145M. The strong guidance, alongside recent acquisitions, drove a sharp near-term rally.
-   **JNBY (3306.HK)**: The fashion apparel maker remains steady after reporting a 54% profit surge for its fiscal first half. Having completed a HKD 272.9M share placement in early 2026, institutions currently rate the stock as "Outperform".
-   **Shenwan Hongyuan HK (0218.HK)**: The financial firm has been aggressively optimizing its capital structure, completing a combined RMB 5.5B in bond redemptions and issuing RMB 3B in new bonds throughout July and August 2026.
-   **Weixun Holdings (0918.HK)**: Following a steep discount stake sale by its controlling shareholder at HKD 1 per share, the company swiftly appointed a new Chief Strategy Officer and Chief Technology Officer in late July, signaling a potential pivot in its drone components business.
-   **China Foods (0506.HK)**: The defensive consumer staple is scheduled to hold a board meeting in late August 2026 to review interim results and consider a dividend payout. The stock remains stable after paying its final dividend last month.

*This article does not constitute investment advice.*

### Related Stocks

- [02697.HK](https://longbridge.com/en/quote/02697.HK.md)
- [09887.HK](https://longbridge.com/en/quote/09887.HK.md)
- [02656.HK](https://longbridge.com/en/quote/02656.HK.md)
- [03933.HK](https://longbridge.com/en/quote/03933.HK.md)
- [03306.HK](https://longbridge.com/en/quote/03306.HK.md)
- [08299.HK](https://longbridge.com/en/quote/08299.HK.md)

## Related News & Research

- [Trustee Buys 220,700 H Shares Under Award Scheme](https://longbridge.com/en/news/305773301.md)
- [Guangdong True Health Names Yip Man Wai Joint Company Secretary](https://longbridge.com/en/news/305306668.md)
- [Guangzhou Industry Investment-Backed Shuimu Medical Opens Device Testing Center in Huangpu](https://longbridge.com/en/news/305092883.md)
- [China Accepts United Laboratories’ Semaglutide Weight-Management Application](https://longbridge.com/en/news/304289761.md)
- [Guotai Haitong Sticks to Its Buy Rating for JNBY Design (JNBYF)](https://longbridge.com/en/news/301540870.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**